Lisata Therapeutics Stock Buy Hold or Sell Recommendation
| LSTA Stock | USD 3.73 0.02 0.54% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Lisata Therapeutics is 'Hold'. Macroaxis provides Lisata Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LSTA positions.
Check out Lisata Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide. In addition, we conduct extensive research on individual companies such as Lisata and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Lisata |
Execute Lisata Therapeutics Buy or Sell Advice
The Lisata recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lisata Therapeutics. Macroaxis does not own or have any residual interests in Lisata Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lisata Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | OK | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Lisata Therapeutics Trading Alerts and Improvement Suggestions
| Lisata Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from prnewswire.com: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit |
Lisata Therapeutics Returns Distribution Density
The distribution of Lisata Therapeutics' historical returns is an attempt to chart the uncertainty of Lisata Therapeutics' future price movements. The chart of the probability distribution of Lisata Therapeutics daily returns describes the distribution of returns around its average expected value. We use Lisata Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lisata Therapeutics returns is essential to provide solid investment advice for Lisata Therapeutics.
| Mean Return | 0.45 | Value At Risk | -4.56 | Potential Upside | 7.84 | Standard Deviation | 4.26 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lisata Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lisata Stock Institutional Investors
| Shares | Tower Research Capital Llc | 2024-09-30 | 1.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.5 K | Ubs Group Ag | 2024-09-30 | 125 | Royal Bank Of Canada | 2024-09-30 | 52.0 | Jpmorgan Chase & Co | 2024-09-30 | 15.0 | Barclays Plc | 2024-09-30 | 7.0 | Wells Fargo & Co | 2024-09-30 | 1.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 1.0 | Steward Partners Investment Advisory, Llc | 2024-09-30 | 0.0 | Bml Capital Management Llc | 2024-09-30 | 284.7 K | Vanguard Group Inc | 2024-09-30 | 186.4 K |
Lisata Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 2.5M | 8.1M | 7.5M | (9.6M) | (11.0M) | (10.4M) | |
| Free Cash Flow | (8.8M) | (22.3M) | (21.5M) | (20.0M) | (18.0M) | (18.9M) | |
| Depreciation | 63K | 55K | 69K | 189K | 217.4K | 206.5K | |
| End Period Cash Flow | 16.5M | 24.6M | 32.2M | 22.6M | 26.0M | 27.3M | |
| Other Non Cash Items | 307K | 2.5M | 31.2M | (957K) | (1.1M) | (1.0M) | |
| Net Income | (8.1M) | (27.5M) | (54.2M) | (20.8M) | (18.8M) | (19.7M) | |
| Investments | (7.3M) | (54.8M) | 28.9M | 10.1M | 11.6M | 12.2M |
Lisata Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lisata Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lisata Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lisata stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.44 | |
β | Beta against Dow Jones | 0.05 | |
σ | Overall volatility | 4.39 | |
Ir | Information ratio | 0.1 |
Lisata Therapeutics Volatility Alert
Lisata Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Lisata Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Lisata Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Lisata Therapeutics Fundamentals Vs Peers
Comparing Lisata Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lisata Therapeutics' direct or indirect competition across all of the common fundamentals between Lisata Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lisata Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lisata Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lisata Therapeutics to competition |
| Fundamentals | Lisata Therapeutics | Peer Average |
| Return On Equity | -0.44 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Current Valuation | (4.53 M) | 16.62 B |
| Shares Outstanding | 8.39 M | 571.82 M |
| Shares Owned By Insiders | 19.12 % | 10.09 % |
| Shares Owned By Institutions | 9.07 % | 39.21 % |
| Number Of Shares Shorted | 19.13 K | 4.71 M |
| Price To Book | 0.92 X | 9.51 X |
| EBITDA | (25.52 M) | 3.9 B |
| Net Income | (20.84 M) | 570.98 M |
| Cash And Equivalents | 72.99 M | 2.7 B |
| Cash Per Share | 18.07 X | 5.01 X |
| Total Debt | 305 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 22.33 X | 2.16 X |
| Book Value Per Share | 5.91 X | 1.93 K |
| Cash Flow From Operations | (20.03 M) | 971.22 M |
| Short Ratio | 1.79 X | 4.00 X |
| Earnings Per Share | (2.51) X | 3.12 X |
| Price To Earnings To Growth | (0.02) X | 4.89 X |
| Target Price | 14.0 | |
| Number Of Employees | 25 | 18.84 K |
| Beta | 1.22 | -0.15 |
| Market Capitalization | 31.15 M | 19.03 B |
| Total Asset | 54.69 M | 29.47 B |
| Retained Earnings | (528.08 M) | 9.33 B |
| Working Capital | 47.33 M | 1.48 B |
| Net Asset | 54.69 M |
Note: Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 [view details]
Lisata Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lisata . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 4337.28 | |||
| Daily Balance Of Power | 0.0714 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 3.77 | |||
| Day Typical Price | 3.76 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | 0.02 |
About Lisata Therapeutics Buy or Sell Advice
When is the right time to buy or sell Lisata Therapeutics? Buying financial instruments such as Lisata Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lisata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold and Gold Mining Thematic Idea Now
Gold and Gold Mining
Large and mid-size companies, ETFs and funds that are either investing, exploring or producing, gold or indirectly involved in trading or making gold products. The Gold and Gold Mining theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold and Gold Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lisata Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.